Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review

Table 3

Functional efficacious outcomes of the included studies.

Author	Efficacy outcomes	Description, n (%)
Della-Torre et.al.	PaO2/FiO2 ratio; n (%)	200–300 mm of Hg
		Total: 4 (7)
		Sarilumab: 1 (4)
		Comparison: 3 (11)
		value: 0.61
		100–200 mm of Hg
		Total: 22 (39)
		Sarilumab: 10 (36)
		Comparison: 12 (43)
		value: 0.78
		<100 mm of Hg
		Total: 30 (54)
		Sarilumab: 17 (60)
		Comparison: 13 (46)
		value: 0.42
	Mortality; n (%)	Sarilumab: 2 (7)
		Comparison: 5 (18)
		value: 0.42
	Clinical improvement; n (%)	Sarilumab: 17 (60)
		Comparison: 18 (64)
		value: 0.99
	Mechanical ventilation; n (%)	Sarilumab: 6 (21)
		Comparison: 7 (25)
		value: 0.99
Montesarchio et.al.	PaO2/FiO2 ratio	122 (83–240)
	Mortality; n (%)	5 (33.3)
	Intubated vs. not intubated; n (%)	8 (53.3) vs. 7 (46.7)
Benucci et.al.	PaO2/FiO2 ratio	Improvement of oxygenation expressed by an increased SpO2/FiO2 ratio (Horovitz index) by 50 or higher compared to nadir SpO2/FiO2 for at least 48 hours: seven of them showed an improvement of the Horovitz index
	Mortality; n	7 survived and 1 died
Lescure et.al.	PaO2/FiO2 ratio	Total: 237·5 (173·6–300·0)
		Placebo: 240·0 (190·0–332·1)
		Sarilumab (200 mg): 230·0 (165·0–296·9)
		Sarilumab (400 mg): 237·5 (172·7–293·8)
	Mortality (seven-point scale); n (%)	Total: 9 (11%)
		Sarilumab (200 mg): 17 (11%)
		Sarilumab (400 mg): 18 (10%)
	Noninvasive ventilation; n (%)	Total: 7 (2%)
		Placebo: 2 (2%)
		Sarilumab (200 mg): 3 (2%)
		Sarilumab (400 mg): 2 (1%)
	Invasive mechanical ventilation; n (%)	Total: 48 (12%)
		Placebo: 9 (11%)
		Sarilumab (200 mg): 16 (10%)
		Sarilumab (400 mg): 23 (13%)
Gremese et.al.	PaO2/FiO2 ratio	No ICU care: 167.5 (125.4–226.5)
		ICU care: 101.0 (89.0–141.0)
		value: 0.007
	Mortality; n (%)	No ICU care: 1 (2.5%)
		ICU care: 2 (14.2%)

ICU: intensive care unit.